Drug Profile
Alfimeprase - Nuvelo
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Amgen
- Class Antithrombotics; Metalloendopeptidases; Thrombolytics; Vascular disorder therapies
- Mechanism of Action Fibrinolytic agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Catheter thrombosis; Peripheral arterial occlusive disorders; Stroke
Most Recent Events
- 17 Mar 2008 Discontinued - Phase-II for Stroke in Canada (Intra-arterial)
- 17 Mar 2008 Discontinued - Phase-II for Stroke in USA (Intra-arterial)
- 17 Mar 2008 Discontinued - Phase-III for Catheter thrombosis in USA (Intra-arterial)